CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,255 enrolled
Drug / intervention
Benralizumab Arm A +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02155660
NCT02155660Phase 3Completed
CompareCT.gov

A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.

AstraZeneca·interventional·Posted Jun 4, 2014·Updated Jun 26, 2019

In Brief

A Phase 3 clinical trial evaluating Benralizumab Arm A, Benralizumab Arm B, and 2 other interventions for Moderate to Very Severe Chronic Obstructive Pulmonary Disease. Completed, enrolled 2,255 participants across 356 sites in 26 countries.

Detailed Summary

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Very Severe Chronic Obstructive Pulmonary Disease
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Chile, Colombia, Croatia, Denmark, France, Israel, Mexico, New Zealand, Norway, Peru, Philippines, Poland, Serbia, Slovenia, Sweden, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United States, Vietnam
CollaboratorsMedImmune LLC

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 4, 2014
Enrollment StartJun 25, 2014
Primary CompletionApr 9, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.1 years ago

Interventions

Benralizumab Arm Adrug

Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Benralizumab Arm Bdrug

Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Benralizumab Arm Cdrug

Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Placebodrug

Benralizumab subcutaneously on study week 0 until study week 48 inclusive